Skip to main content
TipRanks
Go Ultimate75% OFF

Zai Lab (ZLAB) Q3 2026 Earnings Report

729 Followers

ZLAB Q3 2026 EPS Results

Actual EPS
-$0.41
Consensus EPS
-$0.59
Beat/Miss
Beat by +$0.18
One Year Ago EPS
-$0.33

ZLAB Q3 2026 Revenue Results

Actual Revenue
$108.50M
Expected Revenue
$107.90M
Beat/Miss
Beat by +$597.46K
YoY Revenue Growth
-6.67%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/05/2026
Time
Before Open
Conference Call
Thursday, November 5, 2026
ZLAB Upcoming Earnings

Zai Lab's next earnings date is estimated for March 2, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

ZLAB Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 05, 2026|% Change Since:-3.86%|
Earnings Call Sentiment|Positive

The call was strongly positive, driven by zoci's high response rate, encouraging progression-free survival and tolerability data, multiple potential 2027 regulatory milestones, progress across the global pipeline, a profitable China commercial business, disciplined operating expenses, and a strengthened balance sheet. The main challenges were that China product revenue has not yet returned to year-over-year growth, ZEJULA faces pricing and competitive dynamics, and several regulatory and strategic outcomes remain dependent on future clinical data.

Company Guidance

Zai Lab expects three registrational studies underway by year-end across small cell lung cancer and neuroendocrine carcinomas, two registrational results and its first potential U.S. BLA submission in 2027, a U.S. launch as early as 2028, and a return to year-over-year product revenue growth in 2027, with “meaningful growth” expected from VYVGART SubQ, KarXT, ZEJULA, XACDURO, NRDL coverage and stabilization of the mature portfolio. The company expects three additional oncology and immunology assets in clinical development next year, plans a global phase III study of zoci 1.6 mg per kg plus immunotherapy, expects an interim analysis in 2027 could support a U.S. BLA submission for accelerated approval in second-line and later disease, and expects final epNEC results and a potential submission in 2027; the epNEC confirmatory study will start early next year. For DLLEVATE, the response rate accelerated approval analysis will include 200 patients, with six months after the first scan assessment to assess durability of response, and all patients must be approved by the time this analysis is done.

  • Zoci Advancing Toward Major Regulatory and Commercial MilestonesZai Lab expects three registrational studies to be underway by year-end across small cell lung cancer and neuroendocrine carcinomas, two registrational results in 2027, and a potential first U.S. BLA submission for zoci in 2027, with a potential U.S. launch as early as 2028.
  • Strong First-Line Small Cell Lung Cancer EfficacyIn 33 efficacy-evaluable previously untreated patients receiving zoci plus atezolizumab at 1.6 mg per kg, confirmed objective response rate was 81.8%. Estimated six-month progression-free survival was 81.9%, while median progression-free survival and median duration of response had not been reached among the first 15 patients with a median follow-up of 10 months.
  • Favorable Zoci Tolerability ProfileAt the 1.6 mg per kg dose, grade three or higher zoci-related adverse events occurred in 9.1% of patients, with one reported case of grade one interstitial lung disease. Management cited historical grade three or higher treatment-related adverse events of roughly 60% or more with chemo-IO.
  • Expansion of Zoci Development and Combination StrategyZai Lab is advancing the zoci 1.6 mg per kg plus immunotherapy doublet into a global randomized phase III study and is developing combinations with T-cell engagers through collaborations with Amgen and BI. The global phase Ib study with Amgen is progressing, including evaluation in tarlatamab progressors and treatment-naive patients.
  • DLLEVATE Study Supports Potential Accelerated Approval PathThe registrational phase III DLLEVATE study is evaluating zoci in second-line and later small cell lung cancer, including patients previously treated with tarlatamab. A formal response-rate interim analysis is expected to include 200 patients, with six months of follow-up after the first scan assessment; contingent on sufficient post-tarlatamab enrollment and the results, the analysis could support a U.S. BLA submission for accelerated approval in 2027.
  • Progress in Extrapulmonary Neuroendocrine CarcinomasZai Lab completed enrollment in its phase I/II second-line epNEC study and planned to present preliminary results from approximately 60 patients. The company said it has two single-arm data sets totaling about 100 patients and is pursuing a potential accelerated approval supported by those studies, with final results and a potential submission expected in 2027.
  • ZL-1503 Advances in Atopic DermatitisThe internally developed long-acting IL-13/IL-31 receptor alpha bispecific ZL-1503 met the pre-specified endpoints of its single ascending dose study in healthy volunteers. Zai Lab plans to present safety, pharmacokinetic, immunogenicity, and sustained IL-13 pathway inhibition data, followed by clinical efficacy and itch-control data and initial IV-to-subcutaneous bridging data next year. Phase IIb development is being planned.
  • Broader Global and China Pipeline ProgressAdditional global assets advancing include ZL-6201, an LRRC15-targeted ADC; ZL-1311, a MUC17-targeting T-cell engager; and ZL-1222, a PD-1/IL-12 immunocytokine. The China regional pipeline also includes potential additional filings for efgartigimod and ongoing registrational development of elegrobart in thyroid eye disease.
  • China Commercial Business Stabilized and Remained ProfitableNet product revenue increased 2% sequentially, and the China commercial business remained profitable. Management said this performance was consistent with the stabilization described on the prior quarterly call and maintained its expectation for a return to year-over-year product revenue growth in 2027.
  • Quarterly Revenue and Cost DisciplineThird-quarter total revenue was $108.2 million. R&D and SG&A expenses remained relatively stable compared with the prior-year period, reflecting operational efficiency and resource-optimization initiatives.
  • Strengthened Balance SheetCash was $659.7 million as of September 30, 2026. In October, Zai Lab raised approximately $250 million in equity at no discount to market, providing additional financial flexibility to continue investing in its highest-value opportunities.
  • Priority Brand Performance and 2027 Growth DriversVYVGART volumes continued to grow sequentially on new patient starts, KarXT gained traction ahead of potential NRDL inclusion next year, and management said ZEJULA regained important patient share. The company also expects growth from VYVGART SubQ, KarXT, core brands, ZEJULA, and XACDURO as its supply constraint is relieved.
  • NUZYRA Sales Outperformed ExpectationsManagement said NUZYRA sales were stronger than expected in the quarter, attributed this to a strong partnership with its partners, and stated that NUZYRA could be one of the drivers of the total business going forward.
  • Zai Lab Plans to Advance Zoci IndependentlyManagement said its current plan is to take zoci forward itself, with planning already underway. The company remains open to evaluating global partnership options that could accelerate patient access or increase shareholder value without changing the pace or urgency of its development program.

ZLAB Earnings History

ZLAB earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 02, 20272026 (Q4)-0.52--0.46――
Nov 05, 20262026 (Q3)-0.59-0.41-0.33-24.24% (-0.08)
Aug 06, 20262026 (Q2)-0.68-0.50-0.37-35.14% (-0.13)
May 07, 20262026 (Q1)-0.53-0.46-0.45-2.22% (-0.01)
Feb 26, 20262025 (Q4)-0.36-0.46-0.842.50% (+0.34)
Nov 06, 20252025 (Q3)-0.29-0.33-0.4221.43% (+0.09)
Aug 07, 20252025 (Q2)-0.36-0.37-0.8254.88% (+0.45)
May 08, 20252025 (Q1)-0.55-0.45-0.5518.18% (+0.10)
Feb 27, 20252024 (Q4)-0.65-0.80-1.6350.92% (+0.83)
Nov 12, 20242024 (Q3)-0.78-0.42-0.07-500.00% (-0.35)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed